Bionano Capital Stock vs Long Term Debt Total Analysis
BNGO Stock | USD 1.14 0.03 2.70% |
Bionano Genomics financial indicator trend analysis is way more than just evaluating Bionano Genomics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bionano Genomics is a good investment. Please check the relationship between Bionano Genomics Capital Stock and its Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.
Capital Stock vs Long Term Debt Total
Capital Stock vs Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bionano Genomics Capital Stock account and Long Term Debt Total. At this time, the significance of the direction appears to have strong relationship.
The correlation between Bionano Genomics' Capital Stock and Long Term Debt Total is 0.69. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Bionano Genomics, assuming nothing else is changed. The correlation between historical values of Bionano Genomics' Capital Stock and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Bionano Genomics are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Capital Stock i.e., Bionano Genomics' Capital Stock and Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | 0.69 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Long Term Debt Total
Most indicators from Bionano Genomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bionano Genomics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.At this time, Bionano Genomics' Tax Provision is very stable compared to the past year. As of the 18th of May 2024, Selling General Administrative is likely to grow to about 98.2 M, while Enterprise Value Over EBITDA is likely to drop (0.83).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 927K | 298K | 5.1M | 5.4M | Depreciation And Amortization | 177K | 1.3M | 13.7M | 14.4M |
Bionano Genomics fundamental ratios Correlations
Click cells to compare fundamentals
Bionano Genomics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bionano Genomics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 30.2M | 60.4M | 377.1M | 307.5M | 214.4M | 142.9M | |
Short Long Term Debt Total | 20.0M | 16.3M | 10.7M | 11.7M | 87.9M | 92.3M | |
Other Current Liab | 3.2M | 5.6M | 9.7M | 19.9M | 8.1M | 8.9M | |
Total Current Liabilities | 26.3M | 8.9M | 21.8M | 35.9M | 100.0M | 105.0M | |
Total Stockholder Equity | 3.6M | 35.1M | 337.1M | 249.4M | 96.2M | 89.9M | |
Other Liab | 227.1K | 97.9K | 9.2M | 13.1M | 15.1M | 15.8M | |
Net Tangible Assets | 3.6M | 26.4M | 337.1M | 172.1M | 197.9M | 207.8M | |
Property Plant And Equipment Net | 1.9M | 4.9M | 20.9M | 29.0M | 32.5M | 34.1M | |
Current Deferred Revenue | 357.5K | 415.5K | 684K | 871K | 783K | 555.6K | |
Net Debt | 2.7M | (22.1M) | (13.9M) | 6.6M | 34.9M | 36.6M | |
Retained Earnings | (102.6M) | (143.7M) | (216.1M) | (348.7M) | (581.2M) | (552.1M) | |
Accounts Payable | 2.7M | 2.9M | 9.7M | 12.5M | 10.4M | 5.9M | |
Cash | 17.3M | 38.4M | 24.6M | 5.1M | 53.1M | 55.7M | |
Non Current Assets Total | 1.9M | 13.7M | 104.7M | 150.2M | 74.3M | 48.6M | |
Non Currrent Assets Other | (1.9M) | 102.6K | 749K | 2.8M | 7.4M | 7.8M | |
Cash And Short Term Investments | 17.3M | 38.4M | 250.6M | 113.2M | 101.9M | 74.8M | |
Net Receivables | 6.3M | 2.8M | 4.9M | 7.0M | 9.7M | 5.6M | |
Common Stock Total Equity | 3.4K | 19.0K | 29K | 30K | 34.5K | 36.2K | |
Common Stock Shares Outstanding | 1.5M | 10.4M | 27.7M | 28.9M | 34.2M | 35.9M | |
Liabilities And Stockholders Equity | 30.3M | 60.4M | 377.1M | 307.5M | 214.4M | 142.9M | |
Non Current Liabilities Total | 335.0K | 16.4M | 18.1M | 22.2M | 18.2M | 16.2M | |
Capital Surpluse | 106.2M | 178.7M | 553.7M | 599.2M | 689.1M | 723.5M | |
Inventory | 3.4M | 3.3M | 12.4M | 29.8M | 22.9M | 24.0M | |
Other Current Assets | 1.2M | 2.2M | 4.5M | 7.3M | 5.7M | 3.2M | |
Other Stockholder Equity | 106.2M | 178.7M | 553.7M | 599.2M | 677.3M | 711.2M | |
Total Liab | 26.6M | 25.4M | 40.0M | 58.1M | 118.2M | 124.2M | |
Property Plant And Equipment Gross | 1.9M | 4.9M | 10.3M | 29.0M | 51.6M | 54.1M | |
Total Current Assets | 28.3M | 46.8M | 272.4M | 157.3M | 140.1M | 94.3M | |
Non Current Liabilities Other | 808.4K | 44.5K | 18.0M | 22.1M | 10.9M | 8.4M | |
Common Stock | 3.4K | 19.0K | 29K | 30K | 5K | 4.8K | |
Property Plant Equipment | 1.9M | 4.9M | 10.3M | 18.0M | 20.7M | 21.8M | |
Net Invested Capital | 23.7M | 51.4M | 337.1M | 249.4M | 166.0M | 126.2M | |
Net Working Capital | 1.9M | 37.8M | 250.6M | 121.4M | 40.1M | 72.4M | |
Retained Earnings Total Equity | (102.6M) | (143.7M) | (216.1M) | (348.7M) | (313.8M) | (298.2M) | |
Deferred Long Term Liab | 182.6K | 97.9K | 146K | 127K | 114.3K | 137.3K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Bionano Stock analysis
When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.81) | Revenue Per Share 1.058 | Quarterly Revenue Growth 0.305 | Return On Assets (0.33) | Return On Equity (1.35) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.